Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors

Diabetic kidney disease remains the leading cause of end‐stage kidney disease and a major risk factor for cardiovascular disease. Large cardiovascular outcome trials and dedicated kidney trials have shown that sodium‐glucose cotransporter (SGLT)2 inhibitors reduce cardiovascular morbidity and mortal...

Descripción completa

Detalles Bibliográficos
Autores principales: Scholtes, Rosalie A., van Baar, Michaël J. B., Kok, Megan D., Bjornstad, Petter, Cherney, David Z. I., Joles, Jaap A., van Raalte, Daniël H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026736/
https://www.ncbi.nlm.nih.gov/pubmed/33283420
http://dx.doi.org/10.1111/nep.13839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026736/
https://www.ncbi.nlm.nih.gov/pubmed/33283420
http://dx.doi.org/10.1111/nep.13839

Ejemplares similares